Frontiers
Browse
Image_1_A Novel Antibody-Toxin Conjugate to Treat Mantle Cell Lymphoma.TIF (61.76 kB)

Image_1_A Novel Antibody-Toxin Conjugate to Treat Mantle Cell Lymphoma.TIF

Download (61.76 kB)
figure
posted on 2019-04-10, 04:16 authored by Gulam M. Rather, Siang-Yo Lin, Hongxia Lin, Zoltan Szekely, Joseph R. Bertino

Matriptase is a transmembrane serine protease, synthesized as an inactive single-chain zymogen on the endoplasmic reticulum and transported to the plasma membrane. Matriptase is activated in different epithelial and some B-cell malignancies and changes its conformation and activity is inhibited mainly by its endogenous inhibitor HAI-1. Activated matriptase plays a key role in tumor initiation as well as tumor progression, including invasiveness, and metastasis. To target the anti-mitotic toxin (monomethyl auristatin-E) to activated matriptase, a novel antibody to activated matriptase was conjugated with this toxin via a valine-citrulline-PABA linker. In a previous study, this antibody-toxin conjugate was found to be effective against triple negative breast cancer cell lines and xenografts, alone, or in combination with cisplatin (1). In this study, we examined the anti-tumor effect of the antibody toxin conjugate (ADC) against activated matriptase positive mantle cell lymphoma cell lines (JeKo-1, Maver, Mino, and Z138). This ADC was cytotoxic to these cell lines with IC50s between 5 and 14 μg/mL. The ADC also showed a dose dependent anti-tumor effect on the JeKo-1 xenograft in mice without toxicity.

History